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In spite of a great number of the existing drugs and methods, as well as introduction of the new ones, the problem of 
improving the treatment of patients with psoriasis and psoriatic arthritis is still one of the most burning and topical in 
modern dermatology. In case of such disorders, glucocorticoids are the most effective if combined with keratolytics – the 
effective agents facilitating the drug penetration directly to the affected area. The aim of the work was to study the specific 
pharmacological activity of Dermabin medicine on the model of contact dermatitis in rats compared to Diprosalik. In order to 
reproduce this pathology rats were applied 2,4-dinitrochlorobenzene in the form of 5% ethanol–acetone solution twice a 
day for 4 days. In 4 days after the first application the area affected by contact dermatitis (CD) was covered with Derma-
bin or the reference medicine Diprosalic for 14 days. The severity of psoriasis developed was assessed daily based on the 
change of the skin covering indices: the skin fold thickness and the severity of skin manifestation. It was registered that 
in animals with the test and reference medicines applied the hemorrhagic crusting began exfoliating on the 4th day of the 
treatment, which was twice faster than in rats of the control group, and the skin fold thickness significantly decreased. On the 7th 
and 10th days of the treatment the progressive improvement of the CD affected area was observed in these animals. On the 
14th day all rats receiving the active treatment showed significant restoration of their appearance, and the ESR index de-
creased almost to the level observed in intact animals. At the same time the severity of leucocytosis also reduced. Therefore, 
the results obtained indicate the marked anti-inflammatory activity of Dermabin medicine in rats with the experimental 
model of contact dermatitis.Psoriasis is a chronic recur- rent genetically determined disease of multifactorial nature, which is characterized by staging, 
immune-dependent inflammation, benign hyperproliferation of epi- dermal cells with their abnormal differentiation accompanied with papulosquamous rash, as well as the possible involvement of the locomotor apparatus and visce- ral organs to the pathological pro- cess. The main peculiarities of this dermatosis are the etiology of the disease that has not been entire- ly understood, complexity of pa- thogenic mechanisms of develop- ment, frequent recurrence with short disease-free survivals, im- pairment of the patient’s life, de- crease of their professional acti- vity and social integration, the fre- quent development of complica- ted forms, the increase in the num- ber of cases of the patients’ long-
term incapacity for employment and disability [10, 13].The main cause of this auto- immune disease is considered to be disorders of the immune sys-tem, which attacks the cells of the own organism by mistake leading 
to skin inflammation and exces-sive cell proliferation [17]. The re- sults of many studies prove the leading role of T-lymphocytes and macrophages in development of autoimmune aggression upon skin cells [11, 18]. In recent years much data on the important role of che- mokines in the processes of leu- kocyte migration and distribution in psoriasis have appeared. It has been shown that populations of ef- fector T-lymphocytes release CLA and CCR4 chemokines [8, 21]. CCL20, CCL27 and monokine induced by 
γ-interferon (MIG) participate in involvement of T-cells to the pso- riatic rash zone [14, 15, 21]. More- 
over, in psoriasis the release of an- 
giogenic factors and pro-inflam-
matory cytokines intensifies, and 
the level of anti-inflammatory cy- tokines decreases [9, 22].In spite of a great number of the existing drugs and methods, as well as introduction of the new ones, the problem of improving the treatment of patients with pso- riasis and psoriatic arthritis is still one of the most burning and topi- cal in modern dermatology. The treatment success criteria are the time of the clinical effect onset, the skin cleansing from rash, remis- sion duration, improvement of qua- lity of the patient’s life. Not least important is the high level of sa- fety, tolerability and comfort of ap- plication [4, 19]. The most active 
drugs of the anti-inflammatory the- rapy are glucocorticoids posses- sing the vasoconstrictive and mem- brane-stabilizing action; they have the suppressor effect on immune factors, inhibit production of pro- 
inflammatory cytokines and re-duce cell proliferation in the af-fected area [20].V.L.Karbovskyy – Candidate of Biology (PhD), Deputy Director for Science and Technology of LLC “Pharmaceutical Plant “Biofarma”” (Bila Tserkva)  T.Ye.Makovska – cardiologist of the Main Military Medical Hospital (Kyiv)
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nisation disorders the efficiency of the therapy with topical ste- 
roids is significantly increased if combined with keratolytics – the effective agents facilitating the drug penetration directly to the affec- ted area. Combined medicines of corticosteroids with keratolytics, in particular with salicylic acid, 
provide more significant thera-peutic action in case of psoriasis than each drug individually. Sali- cylic acid has the keratolytic ef- fect at the stratum corneum level of the epidermis, and a cortico- steroid penetrates to deeper skin layers and inhibits the synthesis 
of pro-inflammatory cytokines and reduces the vessel wall permeabi- lity in the uppermost layer of the dermis [16]. Dermabin ointment 
(produced by “Pharmaceutical 
Plant “Biofarma” LLC) contains salicylic acid and betamethasone dipropionate. Therefore, the aim of the work was to study the spe-
cific pharmacological activity of Dermabin medicine on the model of contact dermatitis in rats com- pared to Diprosalik.
Materials and Methods
The specific pharmacological 
activity of Dermabin (“Pharma- ceutical Plant “Biofarma” LLC, Bila Tserkva, Ukraine, ointment in tubes, 15 g; its 1 g contains beta- methasone dipropionate, being equivalent to 0.5 mg of betame- thasone, and 30 mg of salicylic 
acid) was assessed on the model 
of contact dermatitis (CD). In or- der to reproduce this pathology rats were applied 2,4-dinitrochlo- robenzene in the form of 5% etha- nol–acetone solution on the skin 
areas (9 cm2) previously clipped twice a day for 4 days [2]. In 4 days 
after the first application the af- fected CD area was covered with Dermabin or the reference medi- 
cine Diprosalic (Schering-Plough Labo N.B., Belgium, ointment in tubes, 15 g; its 1 g contains beta- methasone dipropionate, being equivalent to 0.5 mg of betame- 
thasone, and 30 mg of salicylic acid). 
The medicines were applied dai-ly once a day for 14 days. The se-verity of psoriasis developed was assessed daily based on change of the skin covering indices: the skin fold thickness and the seve- rity of skin manifestation. The skin manifestation severity was asses- sed in points from 0 to 5 by the skin testing scale [6]: 0 – no re-action; 0.5 – appearance of local foci of hyperemia; 1 – marked hy- peremia; 2 – hyperemia and ede- ma; 3 – abrupt rubefaction and ede- ma; 4 – formation of erosions; 5 – hemorrhagic crusting formation.The experiments were carried out on 40 male white non-pedi- gree rats weighing 190–230 g. All experimental animals were kept in the vivarium in compliance with sanitary standards on the required diet [7]. All studies were perfor- med in accordance with regula- tions of the “European Convention for the Protection of Vertebrate Animals used for Experimental and 
Other Scientific Purposes” [12]. After 10-days isolation period the experimental rats were divided into the following groups by the ran- domization method: group 1 – the 
intact control (n=10); group 2 – animals with the experimental CD 
where Vaseline (ointment in tubes, 30 g, produced by “Phytopharm” 
PJSC, Ukraine) was applied on the 
affected areas (n=10); group 3 – animals with the experimental CD 
+ Dermabin (n=10); group 4 – ani- mals with the experimental CD + 
Diprosalic (n=10). The assessment of the mani-festation severity in the CD area and measurement of the skin fold thickness were performed on the 1st, 4th, 7th, 10th and 14th day of the ex- 
periment. The anti-inflammatory activity of the test and reference medicines was determined on the 14th day of the experiment [1].The peripheral blood indices were determined before applica-tion of the medicines and on the 14th day of the experiment. The ery- 
throcyte sedimentation rate (ESR), white blood count and the percen- tage ratio of certain leukocyte sub- 
populations in the peripheral blood was determined using common me- thods [3].Statistical processing of the re- sults was performed by STATISTI- CA 6.0 application program package 
(StatSoft, USA) using Student’s t-test, Mann-Whitney U-test and Wilcoxon signed-ranks test [5]. 
At р<0.05 the differences between control and experiment were con- 
sidered to be significant.
Results and DiscussionThe results showed that after 4 days of 2,4-dinitrochlorobenze- ne application the CD area was for- med on the rats’ skin, it was cha- racterized by vesicular skin rash, excoriation and formation of a thick, heavy and deep hemorrhagic cru- sting. In the affected area and de- pendent areas the edema and in- 
flammatory cells developed, the skin fold increased, its thickness reached 5–6 mm, while in the in- tact animals it was on the average 
2.2 mm (p<0.05, Table 1). The skin manifestation severity in three ex- perimental groups was 4.8±0.13 
points (p<0.05 compared to the group of intact animals where it 
was 0). This day was considered 
to be the first day of the therapy, when application of Vaseline, Der- mabin and the reference medici- ne Diprosalic was started direct-ly on the CD area.
In the animals of group 2 (CD 
+ Vaseline) improvements occur- red on the 10th day of observation and were evident by the decrease of the skin damage severity on the 
average up to 4.1 points (Table 1). The skin fold thickness decreased by 25% compared to the corre- sponding index on the 1st day. In that period in 30% of rats of this group almost compete exfo- liation of hemorrhagic crusting for- med during dinitrochlorobenze- ne application was observed, and in the rest of animals only some fragments remained. Complete ex- foliation in all animals was over by the 14th day of observation, however, in that period hypere- mia and a slight increase of skin 
КЛІНІЧНА ФАРМАЦІЯ. – 2016. – Т. 20, № 432 ISSN 1562-725Xfold thickness was observed com- pared to intact animals.In the animals of groups 3 and 4 with application of the test and reference medicine on the CD area the hemorrhagic crusting began exfoliating on the 4th day of the treatment, which was twice faster than in rats of CD + Vaseline group. In that period the skin fold thick-ness decreased by 10.9% each in CD + Dermabin group and CD + 
Diprosalic group (р<0.05; Table 1). On the 7th and 10th days of the treat- ment the progressive improvement of the CD affected area was obser- ved. In the groups of the test and reference medicine the skin fold thickness on the 7th day was 17.8 
and 15.6% (p<0.05), and on the 10th day – 20.9 and 18.6% (p<0.05) less compared to the correspon- ding indices of animals of group 2 
(Table 1). On the 14th day all rats receiving active treatment showed 
a significant restoration of their appearance. In CD + Dermabin group the skin fold thickness de- 
creased by 27.8% (p<0.05), and in CD + Diprosalic group by 22.2% 
(p<0.05; Table 1). Therefore, both medicines have the same effect on 
the abovementioned parameters of the experimental CD in rats. Comparative values of the anti- 
inflammatory aсtivity of both me- 
dicines confirm this: Dermabin – 55.2% and Diprosalic – 58.6%.During the experiment the chan- ges of the peripheral blood indi- 
Table 1
The effect of Dermabin and Diprosalic on the severity  
of contact dermatitis (CD) in rats (М±m), n=40
Day of  
the study
The group of 
animals
The severity of skin 
manifestations, score
The skin fold  
thickness, mm
Intact 0 2.2 ± 0.13
Day 1
CD + Vaseline 4.8 ± 0.13# 5.7 ± 0.15#
CD + Dermabin 4.8 ± 0.13# 5.6 ± 0.16#
CD + Diprosalic 4.8 ± 0.13# 5.5 ± 0.17#
Day 4
CD + Vaseline 4.7 ± 0.15 5.5 ± 0.17
CD + Dermabin 4.4 ± 0.16 4.9 ± 0.10*
CD + Diprosalic 4.3 ± 0.15 4.9 ± 0.18*
Day 7
CD + Vaseline 4.5 ± 0.17 4.5 ± 0.22
CD + Dermabin 3.9 ± 0.18* 3.7 ± 0.15*
CD + Diprosalic 3.8 ± 0.20* 3.8 ± 0.13*
Day 10
CD + Vaseline 4.1 ± 0.10 4.3 ± 0.21
CD + Dermabin 3.0 ± 0.15* 3.4 ± 0.16*
CD + Diprosalic 3.0 ± 0.21* 3.5 ± 0.17*
Day 14
CD + Vaseline 2.9 ± 0.18 3.6 ± 0.16
CD + Dermabin 1.3 ± 0.15* 2.6 ± 0.16*
CD + Diprosalic 1.2 ± 0.13* 2.8 ± 0.20*
Note. # – p<0.05 in relation to the intact control group; * – p<0.05 in relation  
to CD + Vaseline group.
Table 2
Indices of the peripheral blood of rats with the experimental contact dermatitis (CD)  
after dermal application of Dermabin and Diprosalic for 14 days (М±m), n=40
Index
The group of animals
Intact CD + Vaseline CD + Dermabin CD + Diprosalic
Day 1
ESR, mm/h 2.3 ± 0.30 5.3 ± 0.50# 5.3 ± 0.30 5.4 ± 0.43
Leucocytes, ×109/l 7.29 ± 0.49 11.29 ± 0.81# 11.5 ± 0.66 11.32 ± 0.96
Segmented neutrophils, % 21.2 ± 0.89 32.3 ± 1.26# 32.6 ± 1.51 33.2 ± 1.43
Banded neutrophils, % 1.5 ± 0.17 3.7 ± 0.30# 3.3 ± 0.37 3.5 ± 0.34
Eosinophils, % 2.0 ± 0.33 3.1 ± 0.23# 2.9 ± 0.35 3.0 ± 0.26
Lymphocytes, % 72.2 ± 0.93 57.4 ± 1.31# 57.8 ± 1.49 56.7 ± 1.46
Monocytes, % 3.1 ± 0.31 3.5 ± 0.22 3.4 ± 0.16 3.6 ± 0.16
Day 14
ESR, mm/h 2.1 ± 0.23 4.1 ± 0.28# 3.0 ± 0.26* 3.1 ± 0.31*
Leucocytes, ×109/l 7.29 ± 0.43 9.50 ± 0.49# 7.99 ± 0.45* 7.88 ± 0.49*
Segmented neutrophils, % 22.3 ± 1.16 30.3 ± 0.88# 27.0 ± 0.97* 27.5 ± 0.95*
Banded neutrophils, % 1.7 ± 0.15 2.4 ± 0.16# 2.0 ± 0.21 1.9 ± 0.23
Eosinophils, % 2.1 ± 0.23 2.5 ± 0.27 2.3 ± 0.21 2.4 ± 0.16
Lymphocytes, % 70.7 ± 1.13 61.4 ± 0.99# 65.1 ± 1.13* 64.9 ± 1.11*
Monocytes, % 3.2 ± 0.20 3.6 ± 0.31 3.3 ± 0.30 3.4 ± 0.43
Note. # – p<0.05 in relation to the intact control group; * – p<0.05 in relation to CD+Vaseline group.
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studied (Table 2). Before the treat- ment all animals with the simu-lated CD showed a typical reac-
tion on inflammation, namely the double increase of ESR, leucocy-tosis, the increase of the neutro-phil percentage with a slight, but 
significant shift to the left.The statistically probable in- crease in the eosinophil count was also registered. The lymphocyte count in animals of the experi-
mental groups was significantly less than in intact animals.The study of ESR and the pe-ripheral blood cell composition conducted on the 14th day of the 
treatment showed a significant im- provement in the group of rats with application of Dermabin or 
Diprosalic medicines on the CD af- 
fected area (Table 2). The ESR in- dex in rats of this group decrea- sed almost to the level observed in intact animals. At the same time the severity of leucocytosis also reduced. The percentage of the main leucocyte subpopulations re- duced almost to the level of intact 
rats. Both medicines (Dermabin 
and Diprosalic) had almost the same effect on the peripheral blood in-dices of rats with the experimen-tal CD. Concerning the indices in CD + Vaseline group there were 
significant differences from the in- dices of intact animals: the high ESR and leucocytosis were obser- ved. The percentage of segment-ed and banded neutrophils was much higher, and that of lym-
phocytes was lower than in in-
tact animals (Table 2).CONCLUSIONSTherefore, the results obtained 
indicate the marked anti-inflam-matory activity of Dermabin me- 
dicine (“Pharmaceutical Plant “Bio- 
farma” LLC) in rats with the ex- perimental model of contact der-matitis. Under conditions of the 
local inflammatory response in- duced by 2,4-dinitrochlorobenze- ne application this medicine sig- 
nificantly reduces the severity of dermatitis developed and decrea- ses the system indices of the in- 
flammatory process. By its pro- perties and composition Derma- bin medicine is highly competi-tive with the reference medicine Diprosalic.REfERENCES
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ДОСЛІДЖЕННЯ СПЕЦИФІЧНОЇ ФАРМАКОЛОГІЧНОЇ АКТИВНОСТІ ПРЕПАРАТУ «ДЕРМАБІН» НА МОДЕЛІ 
ЕКСПЕРИМЕНТАЛЬНОГО КОНТАКТНОГО ДЕРМАТИТУ У ЩУРІВ
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Незважаючи на значну кількість вже існуючих та появу нових лікарських засобів та методів терапії, проблема 
вдосконалення лікування хворих на псоріаз та псоріатичний артрит залишається однією з найгостріших та 
найактуальніших у сучасній дерматології. Найбільш активними засобами протизапальної терапії при цих за-
хворюваннях є глюкокортикостероїдні гормони в комбінації з кератолітичними засобами – ефективними аген-
тами, які полегшують проникність ліків безпосередньо у вогнище ураження. Метою роботи було дослідження 
специфічної фармакологічної активності препарату «Дермабін» у порівнянні з препаратом «Дипросалік» на 
моделі контактного дерматиту у щурів. Для відтворення цієї патології щурам протягом 4-х днів двічі на добу 
робили аплікації 2,4-динітрохлоробензолу у вигляді 5% етанол-ацетонового розчину. Через 4 доби після першої 
аплікації на вогнища уражень наносили препарат «Дермабін» або референтний препарат «Дипросалік» про-
тягом 14 днів. Тяжкість розвиненого дерматиту оцінювали щодня за змінами показників шкірного покриву: 
величиною шкірної складки і тяжкістю шкірних проявів. Показано, що у тварин, яким на вогнище ураження на-
носили дані препарати, вже на 4-ту добу лікування почала відокремлюватись геморагічна кірка вдвічі швидше, 
ніж у щурів контрольної групи, а також спостерігалося вірогідне зменшення товщини шкірної складки. На 7-му 
та 10-ту добу терапії у цих тварин відзначено поступове поліпшення стану вогнища контактного дерматиту. 
На 14-ту добу у всіх щурів, які отримували активне лікування, спостерігалося значне відновлення зовнішнього 
вигляду, а значення ШОЕ знизилося майже до рівня, який спостерігався в інтактних тварин. Одночасно змен-
шилася і вираженість лейкоцитозу. Таким чином, отримані нами результати свідчать про виражену проти-
запальну активність препарату «Дермабін» у щурів з експериментальною моделлю контактного дерматиту.
ИССЛЕДОВАНИЕ СПЕЦИФИЧЕСКОЙ ФАРМАКОЛОГИЧЕСКОЙ АКТИВНОСТИ ПРЕПАРАТА «ДЕРМАБИН» НА МОДЕЛИ 
ЭКСПЕРИМЕНТАЛЬНОГО КОНТАКТНОГО ДЕРМАТИТА У КРЫС
В.Л.Карбовский, И.А.Шевчук, О.В.Куркина, Т.Е.Маковская*
ООО «Фармацевтический завод “Биофарма”», Главный военный медицинский госпиталь*
Ключевые слова: псориаз; контактный дерматит; дермабин; бетаметазона дипропионат; салициловая кислота
Несмотря на значительное количество уже существующих и появление новых средств и методов терапии, про-
блема совершенствования лечения больных псориазом и псориатическим артритом остается одной из самых 
острых и актуальных в современной дерматологии. Наиболее активными средствами противовоспалительной 
терапии при этих заболеваниях являются глюкокортикостероидные гормоны в сочетании с кератолитическими 
средствами – эффективными агентами, которые облегчают проницаемость лекарств непосредственно в очаг по-
ражения. Целью нашей работы было исследование специфической фармакологической активности препарата 
«Дермабин» в сравнении с препаратом «Дипросалик» на модели контактного дерматита у крыс. Для воспроиз-
ведения этой патологии крысам в течение 4-х дней дважды в сутки делали аппликации 2,4 динитрохлорбензо-
ла в виде 5% этанол-ацетонового раствора. Через 4 дня после первой аппликации на очаги поражений наноси-
ли препарат «Дермабин» или референтный препарат «Дипросалик» в течение 14 дней. Тяжесть развившегося 
дерматита оценивали ежедневно по изменениям показателей кожного покрова: величине кожной складки и 
тяжести кожных проявлений. Показано, что у животных, которым на очаг поражения наносили исследуемый 
и референтный препараты, уже на 4-е сутки лечения начала отторгаться геморрагическая корка вдвое быстрее, 
чем у крыс контрольной группы, а также наблюдалось достоверное уменьшение толщины кожной складки. 
На 7-е и 10-е сутки терапии у этих животных отмечено постепенное улучшение состояния очага контактного 
дерматита. На 14-е сутки у всех крыс, получавших активное лечение, наблюдалось значительное восстановле-
ние внешнего вида, а значение СОЭ снизилось почти до уровня, который наблюдался в интактных животных. 
Одновременно уменьшилась и выраженность лейкоцитоза. Таким образом, полученные нами результаты сви-
детельствуют о выраженной противовоспалительной активности препарата «Дермабин» у крыс с экспери-
ментальной моделью контактного дерматита.
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